Inventor
Shrirang KARVE
Inventor
US
Overview
Patents· 42 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%
C12NMicroorganisms or enzymes17%
C07HSugars7%
C12YEnzymes6%
C07CAcyclic or carbocyclic compounds4%
C07DHeterocyclic compounds4%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds4%
C07KPeptides3%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
PatentTitleYear
12,594,245Dry powder formulations for messenger RNA202612,576,030Compositions for delivery of codon-optimized mRNA202612,577,554Methods for purification of messenger RNA202612,569,572Messenger RNA therapy for the treatment of Friedreich's ataxia202612,514,932PEG lipidoid compounds202612,453,759Di-thioester cationic lipids202512,410,422Methods for purification of messenger RNA202512,377,053Cationic polymers202512,370,262Messenger RNA vaccines and uses thereof202512,370,238Composition and methods for treatment of primary ciliary dyskinesia202512,280,147PEG lipidoid compounds202512,280,117Lipid nanoparticle formulations for delivery of MRNA202512,268,754Composition and methods for treatment of ornithine transcarbamylase deficiency202512,257,305Cationic lipid compounds202512,239,735Lipid nanoparticles for delivering mRNA vaccines202512,240,824Vitamin cationic lipids202512,234,446Methods for purification of messenger RNA202512,201,677Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency202512,195,505Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR202512,144,871Stable compositions of MRNA-loaded lipid nanoparticles and processes of making202412,076,439Thioester cationic lipids202412,076,438Compositions, methods and uses of messenger RNA202412,064,515Process of preparing mRNA-loaded lipid nanoparticles202412,060,381Methods for purification of messenger RNA202412,053,551Process of preparing mRNA-loaded lipid nanoparticles202412,016,954CNS delivery of mRNA and uses thereof202411,976,272Methods for purification of messenger RNA202411,975,110Cationic polymers202411,969,480Processes of preparing mRNA-loaded lipid nanoparticles202411,964,051Ribose cationic lipids202411,884,692Methods for purification of messenger RNA202411,820,977Methods for purification of messenger RNA202311,771,653Lipid nanoparticles for delivering mRNA vaccines202311,771,652Lipid nanoparticles for delivering mRNA vaccines202311,692,189Methods for purification of messenger RNA202311,559,561Composition and methods for treatment of primary ciliary dyskinesia202311,547,666Cationic lipids comprising a steroidal moiety202311,530,298Poly(phosphoesters) for delivery of nucleic acids202211,427,535Polyanionic delivery of nucleic acids202211,400,109Subcutaneous delivery of messenger RNA202211,357,726Process of preparing mRNA-loaded lipid nanoparticles202211,173,190Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to TRANSLATE BIO INC (39)· patent assignee history
2021–2026Based in US· patent location history
2023–2025Patents assigned to SANOFI SA (3)· patent assignee history
2023–2025Based in FR· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| TRANSLATE BIO INC | 39 | 2021–2026 |
| SANOFI SA | 3 | 2023–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 39 | 2021–2026 |
| FR | 3 | 2023–2025 |